OPDIVO
Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)
ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...
BMS and Halozyme announce positive results for subcutaneous Opdivo in cancer patients
Following the discontinuation of an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb (BMS) has achieved success with a more ...
Ultimovacsâ cancer vaccine shows survival benefit in BMS combo trial despite missing primary endpoint
Ultimovacs, the Norwegian biotech company, has staged a remarkable comeback for its cancer vaccine candidate. Despite encountering a setback earlier ...
Bristol Myers Squibbâs Opdivo gets FDA approval for early-stage melanoma
Bristol Myers Squibb’s Opdivo has achieved a significant milestone with a new FDA approval that expands its reach into earlier ...
Opdivo plus chemo reduces recurrence risk in early-stage lung cancer surgery
In the arena of perioperative treatment for early-stage non-small cell lung cancer (NSCLC) involving PD-1/L1 inhibitors, the competition among key ...
Ultimovacs Explores Innovative Approaches to Conclude Phase 2 Cancer Trial Amid Prolonged Anticipation for Survival Data
Ultimovacs, a Norwegian biotech company, is grappling with prolonged delays in obtaining midphase melanoma trial data, prompting the company to ...
Blockbuster Cancer Immunotherapy Showdown Ends: Bristol Myers Squibb and AstraZeneca Settle Patents Clash
Bristol Myers Squibb (BMS) and AstraZeneca have quickly resolved patent infringement lawsuits related to their cancer immunotherapies. The companies reached ...
Opdivo Receives Positive CHMP Opinion for Neoadjuvant Treatment of High-Risk NSCLC
On May 26, 2023, Bristol Myers Squibb announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use ...
